1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

Eyes On The Prize: Sen. Sanders’ Push For ‘Prize Fund’ Model For Pharma Ends With A Whimper

 
• By Michael McCaughan

Sen. Bernie Sanders has advocated for alternative models to pay for critical medicines in the US for most of his career. His best chance to advance the idea beyond the talking point stage appears to be ending with a request for a study.

Bernie Sanders at a Senate HELP Committee hearing
Sen. Bernie Sanders, right, has wanted to change biopharma innovation for years, but has not made much progress. • Source: Senate HELP Committee

The reauthorization of a key US government program to fund pandemic preparedness appears to be on track in the Senate after a relatively smooth mark-up of the Pandemic and All-Hazards Preparedness and Response Act by the Health, Education, Labor and Pensions (HELP) Committee on 20 July.

Given the surprisingly contentious tone of the reauthorization debate in the House thus far, it is significant that the Senate appears to have come together behind a bill that includes broader supply chain provisions while still retaining broad bipartisan support

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

Trump’s Rx Pricing Order: The Best-Case And Worst-Case Scenarios

 
• By Derrick Gingery

US trade and tariff leverage might successfully push European and other countries to pay more for medicines, but if not, President Trump’s executive order includes potential US drug withdrawal and other options to entice industry to lower US prices.

Medicare Negotiation Does Not Violate Due Process, Appeals Court Rules, Other Suits At Risk

 
• By Cathy Kelly

Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.

Most Favored Nation Pricing Policy Floated In Medicaid, Coming Back To Medicare?

 
• By Cathy Kelly

President Trump's ongoing interest in the policy, which would ensure the US government pays no more for prescription drugs than the lowest price available in comparable countries, continues to gain attention.

More from Market Access

Brazil’s Drug Pricing Shake Up Calls For More Robust Evidence From Companies

 
• By Francesca Bruce

Brazil’s drug pricing authorities are planning to introduce, among other things, a new drug category for biosimilars to ensure the pricing procedures for such medicines are reflected in the official pricing framework.

Brazil To Upgrade Pricing Framework To Keep Up With Market Developments

 
• By Francesca Bruce

Brazil plans to clarify its medicine pricing framework, for example by outlining the procedures for setting medicine prices and bring it up to date with recent developments in the sector.

England: HTA Sandbox Helping To Assess ‘Challenging’ Drugs And Indications

 
• By Eliza Slawther

England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.